文献速递贫血与红细胞疾病白血病淋巴瘤

CRISPR在血液疾病中的应用:从实验室到临床

CRISPR application in hematological disorders: from bench to bedside.
PubMed 文献 · Blood Adv · 2026-01-01

该综述总结了CRISPR基因编辑在遗传性血液病和血液恶性肿瘤中的转化进展。镰状细胞病、β-地中海贫血和重症联合免疫缺陷的成功案例证明,精准持久的基因修饰可安全有效地应用于人造血细胞。文章比较了核酸酶切割、碱基编辑、先导编辑和转录调控等编辑模式,并讨论了递送、脱靶、制造可扩展性等转化挑战。

要点

  • CRISPR已从实验工具发展为血液学临床验证的治疗平台。
  • 遗传性血液病是CRISPR治疗转化的前沿阵地。
  • CRISPR正用于解析血液肿瘤依赖性和验证治疗靶点。

核心结论

  • CRISPR基因编辑已在遗传性血液病中实现临床验证,并正推动血液恶性肿瘤的机制理解和治疗开发。

研究设计与样本

  • 综述类文章,汇总CRISPR在良性和恶性血液病中的最新进展,比较主要编辑模式并讨论临床转化挑战。

主要发现

  • 镰状细胞病、β-地中海贫血和重症联合免疫缺陷的里程碑式成功表明,精准持久的基因修饰可安全有效地应用于人造血细胞。
  • CRISPR方法通过系统解析癌症依赖性、功能定位遗传弱点和机制驱动的靶点验证,正在改变血液恶性肿瘤的认识和治疗。
  • 工程化细胞疗法(包括编辑的自体和异体免疫效应细胞)正在开发中,旨在增强抗肿瘤疗效、持久性和免疫逃逸。

临床怎么用

  • 血液科医生应关注CRISPR在遗传性血液病和血液肿瘤中的临床转化进展。
  • 了解不同编辑模式(核酸酶切割、碱基编辑、先导编辑、转录调控)的潜在应用和局限。

局限性

  • 递送和制造可扩展性限制更广泛的临床采用。
  • 脱靶和基因毒性风险仍需评估。
  • 肿瘤和免疫异质性以及编辑细胞群的长期持久性和适应性是待解决的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein genome editing has advanced from an experimental tool to a clinically validated therapeutic platform in hematology. Landmark successes in inherited blood diseases, including sickle cell disease, β-thalassemia, and severe combined immunodeficiency, have demonstrated that precise and durable genetic modifications can be safely and effectively implemented in human hematopoietic cells, positioning hematology at the forefront of translational genome editing. Beyond monogenic disease, CRISPR-based approaches are transforming both the biological understanding and treatment of hematologic malignancies by enabling systematic interrogation of cancer dependencies, functional mapping of genetic vulnerabilities, and mechanism-driven target validation, including in vivo and immune-relevant contexts. In parallel, therapeutic applications are emerging through the development of engineered cellular therapies, including edited autologous and allogeneic immune effector cells designed to enhance antitumor efficacy, persistence, and immune evasion. This review synthesizes recent CRISPR-based advances across benign and malignant hematologic diseases. We compare major editing modalities, including nuclease-mediated disruption, base editing, prime editing, and CRISPR-based transcriptional modulation, and highlight key preclinical studies alongside emerging clinical trial data. We also discuss translational challenges that currently limit broader clinical adoption, including delivery and manufacturing scalability, off-target and genotoxicity risks, tumor and immune heterogeneity, and the long-term durability and fitness of edited cell populations. Finally, we outline priorities for the next phase of the field, emphasizing how continued innovation in CRISPR technologies may enable increasingly precise, durable, and mechanism-informed therapeutic strategies in hematology.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ladisa F, Morelli E, Soncini D, et al. CRISPR application in hematological disorders: from bench to bedside. Blood Adv. 2026. PMID: 42263664. doi:10.1182/bloodadvances.2025017417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。